PT-141

Bremelanotide

PT-141 (Bremelanotide) is a melanocortin-receptor agonist acting centrally on arousal pathways — a unique, non-vascular mechanism used to support sexual function for both men and women. Typical Course: Administered on an as-needed basis (1–2mg), timed 45 minutes to 2 hours before activity, with a maximum of one dose per 24 hours and no more than twice per week. Most customers notice effects within 45–90 minutes of administration. What to Expect: Activation of arousal pathways, a fast response onset, a defined duration of effect and mood elevation. Key benefits include a central mechanism that works differently to PDE5 inhibitors, no cardiovascular mechanism, applicability across multiple use cases and fast onset of 45–90 minutes. Considerations & Safety: Nausea is very common on first use, blood pressure elevation is transient, and frequency should not exceed twice weekly. Common side effects include nausea (especially on first use), facial flushing, headache and transient blood pressure elevation. Seek medical attention immediately if you experience severe nausea or vomiting, significant blood pressure elevation with severe headache, effects lasting more than 4 hours, or severe allergic reaction.